RaQualia Pharma Inc. (TYO:4579)

RaQualia Pharma Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,440	3,240	3,340	3,714	3,675	2,345
Short-Term Investments	54.34	3	1	49	250	313
Cash & Short-Term Investments	4,495	3,243	3,341	3,763	3,925	2,658
Cash Growth	62.59%	-2.93%	-11.21%	-4.13%	47.67%	25.79%
Receivables	1,234	1,928	689	603	602	1,205
Inventory	161.39	159	167	147	8	10
Prepaid Expenses	439.93	165	193	188	108	90
Other Current Assets	151.79	187	148	255	179	40
Total Current Assets	6,482	5,682	4,538	4,956	4,822	4,003
Property, Plant & Equipment	439.19	436	529	573	391	299
Long-Term Investments	693.45	598	607	1,306	1,020	897
Goodwill	3,630	3,700	3,865	-	-	-
Other Intangible Assets	30.03	32	37	30	24	33
Long-Term Deferred Tax Assets	63.44	64	78	5	-	-
Other Long-Term Assets	52.9	2	1	1	-	2
Total Assets	11,391	10,514	9,655	6,871	6,257	5,234

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	62.29	73	59	54	128	45
Accrued Expenses	56.98	58	69	54	60	63
Current Portion of Long-Term Debt	512.62	512	512	12	2	-
Current Portion of Leases	85.63	78	69	64	42	21
Current Income Taxes Payable	11.03	320	221	178	237	230
Other Current Liabilities	224.67	234	257	27	24	41
Total Current Liabilities	1,052	1,275	1,187	389	493	400
Long-Term Debt	2,011	2,138	2,651	39	9	-
Long-Term Leases	179.94	171	218	251	167	17
Long-Term Deferred Tax Liabilities	-	-	-	-	2	16
Other Long-Term Liabilities	61.68	35	28	73	89	15
Total Liabilities	3,305	3,619	4,084	752	760	448

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	3,948	3,240	2,720	2,667	2,265	2,256
Additional Paid-In Capital	4,137	3,430	2,910	2,857	2,455	2,446
Retained Earnings	1.75	227	-45	449	773	49
Comprehensive Income & Other	-0.16	-2	-14	146	4	35
Shareholders' Equity	8,087	6,895	5,571	6,119	5,497	4,786
Total Liabilities & Equity	11,391	10,514	9,655	6,871	6,257	5,234

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2,789	2,899	3,450	366	220	38
Net Cash (Debt)	1,706	344	-109	3,397	3,705	2,620
Net Cash Growth	-	-	-	-8.31%	41.41%	26.69%
Net Cash Per Share	68.30	14.30	-5.04	157.22	176.57	124.93
Filing Date Shares Outstanding	26.02	26.02	21.84	21.62	21.6	20.96
Total Common Shares Outstanding	26.02	24.46	21.84	21.62	20.98	20.95
Working Capital	5,430	4,407	3,351	4,567	4,329	3,603
Book Value Per Share	310.81	281.91	255.10	282.98	262.05	228.43
Tangible Book Value	4,426	3,163	1,669	6,089	5,473	4,753
Tangible Book Value Per Share	170.13	129.32	76.43	281.60	260.90	226.86

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 5, 2026

Data Sources Report a data error